News Two more biotechs, Attovia and Braveheart, join the IPO line The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia and Braveheart the latest to make their intentions known.
News Braveheart, AAVantgarde rounds head recent biofinancings Our latest crop of biotech financings has nine-figure rounds for Braveheart and AAVantgarde, with Azalea Therapeutics and NEOK Bio also raising funds.
News Altimmune alcohol use disorder drug hits the mark in phase 2 Altimmune's pemvidutide has been shown to reduce drinking in people with alcohol use disorder, adding to the evidence for GLP-1 drugs in this setting.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.